Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/24/17
End: 11/30/17
Due: 11/30/18
Phase: N/A
Priority: Normal
Start: 07/22/19
End: 10/30/20
Due: 10/30/21
Phase: N/A
Priority: Normal
Start: 09/30/21
End: 12/31/22
Due: 12/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers | NCT03316521 | Amyndas Pharmaceuticals S.A. | user2@example.com | None | 2017-04-24 | 2017-11-30 | 2018-11-30 | - | - | 2025-07-14 |
| A Study of the C3 Complement Inhibitor AMY-101 in Adults With Gingivitis | NCT03694444 | Amyndas Pharmaceuticals S.A. | user2@example.com | None | 2019-07-22 | 2020-10-30 | 2021-10-30 | - | - | 2025-07-14 |
| A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE) | NCT04395456 | Amyndas Pharmaceuticals S.A. | user2@example.com | None | 2021-09-30 | 2022-12-31 | 2023-12-31 | - | - | 2025-07-14 |